Pernix Theraptcs Cmn (PTX) 0.64 $PTX Pernix Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 5:09 AM

Pernix Theraptcs Cmn (PTX) 0.64 $PTX

Pernix Therapeutics Reports Second Quarter 2016 Financial Results and Business Update
GlobeNewswire - Thu Aug 11, 3:01PM CDT
Net Revenue Increased 13% Sequentially Over First Quarter 2016
PTX: 0.64 (+0.04)

Pernix Therapeutics to Report Second Quarter 2016 Financial Results on August 11, 2016
GlobeNewswire - Thu Aug 04, 5:31AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, announced today that the Company will report financial results for the second quarter ended June 30, 2016, after the market close on Thursday, August 11, 2016. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
PTX: 0.64 (+0.04)

Research Report on These Healthcare Sector Equities -- Valeant Pharma, Pernix Therapeutics, Perrigo, and Lipocine
PR Newswire - Mon Aug 01, 6:35AM CDT
The number of individuals who require medical attention and treatment is constantly growing, which is why Healthcare stocks remain in high demand. Earnings growth potential within the healthcare sector is much higher compared with other sectors, opening long-term opportunities for investors. Stock-Callers.com reviews the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Perrigo Co. PLC (NYSE: PRGO), and Lipocine Inc. (NASDAQ: LPCN). Learn more about these stocks by accessing their free research reports at:
PRGO: 90.99 (-0.03), VRX: 29.03 (-1.22), PTX: 0.64 (+0.04), LPCN: 3.37 (-0.17), VRX.TO: 38.09 (-1.51)

Pernix Therapeutics Announces Positive Phase IV Results of Silenor(R) vs. Zolpidem Head-to-Head Arousability Study
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Data demonstrated that Pernix Therapeutics' Silenor 6 mg was superior to zolpidem 10 mg on all measures evaluated.
PTX: 0.64 (+0.04)

Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro(R) ER with BeadTek(TM)
GlobeNewswire - Wed May 25, 7:08AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office has issued U.S. Patent Numbers 9,339,499 ('499 patent), 9,326,982 ('982 patent), and 9,333,201 ('201 patent), covering important safety information related to dosing patients with Zohydro ER with BeadTek. These patents, in addition to the 9,265,760 patent ('760 patent) which issued February 23, 2016, are broadly directed to a method of dosing patients with hepatic impairment with hydrocodone where no adjustment in start dose is needed for patients with mild or moderate hepatic impairment. The '760, '499, '982 and '201 patents expire July 25, 2033.
PTX: 0.64 (+0.04)

Pernix Therapeutics Announces CEO Transition
GlobeNewswire - Wed May 11, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, today announced that Doug Drysdale, after discussions with the Company's Board of Directors, has agreed to step down as Chairman of the Board, Chief Executive Officer and President, and has resigned as a member of the Board of Directors, effective May 9, 2016. John Sedor, a current Director of Pernix Therapeutics, has been appointed Chairman of the Board and Interim Chief Executive Officer of the Company while the Board of Directors searches for a permanent CEO. The Board currently intends that Mr. Sedor will remain as Chairman of the Board when a new CEO is appointed.
PTX: 0.64 (+0.04)

Pernix Therapeutics Overcomes Challenge to Treximet(R) '183 Patent
GlobeNewswire - Mon May 09, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, today announced that on May 6, 2016, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied a petition for inter partes review (IPR) filed by Graybar Pharmaceuticals, LLC (now Gray Square Pharmaceuticals, LLC) against Pozen, Inc. This petition, which was filed on November 12, 2015, sought review of certain claims of U.S. Patent No. 7,332,183 ('183 patent), which expires 2026. The '183 patent is licensed by Pernix and is one of several FDA Orange Book listed patents covering Treximet(R), manufactured and sold by Pernix Therapeutics, (sumatriptan/naproxen sodium), a prescription medication for acute migraine attacks, with or without aura.
PTX: 0.64 (+0.04), POZN: 5.94 (-0.43)

Pernix Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 8:19AM CDT
MORRISTOWN, N.J. (AP) _ Pernix Therapeutics Holdings Inc. (PTX) on Thursday reported a loss of $25.9 million in its first quarter.
PTX: 0.64 (+0.04)

Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Thu May 05, 7:01AM CDT
Pernix Prescriptions Direct Achieves Increased Penetration
PTX: 0.64 (+0.04)

Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016
GlobeNewswire - Thu Apr 28, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, announced today that it will release financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016. Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host a conference call to discuss the results, as follows.
PTX: 0.64 (+0.04)

Pernix Therapeutics to Present at Needham & Company's 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at Needham & Company's 15th Annual Healthcare Conference, as follows.
PTX: 0.64 (+0.04)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launch Investigation of Pernix Therapeutics Holdings, Inc. for Possible Breaches of Fiduciary Duty
PR Newswire - Thu Jan 14, 11:15AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) in connection with possible breaches of fiduciary duty.
PTX: 0.64 (+0.04)

Zogenix, Inc Gained 29% in 2015 -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jan 14, 10:59AM CST
What: 2015 was a great year to be a Zogenix shareholder. The clinical-stage biopharmaceutical company's stock soared more than 29% higher during the year, according to data from S&P Capital IQ . So what: The year was filled with...
PTX: 0.64 (+0.04), ZGNX: 8.72 (-0.61)

The Zacks Analyst Blog Highlights: Amphastar Pharmaceuticals, Mylan, Pernix Therapeutics Holdings, Eli Lilly and Novo Nordisk
Zacks Equity Research - Zacks Investment Research - Wed Nov 25, 8:30AM CST
The Zacks Analyst Blog Highlights: Amphastar Pharmaceuticals, Mylan, Pernix Therapeutics Holdings, Eli Lilly and Novo Nordisk
NVO: 46.72 (-0.41), PTX: 0.64 (+0.04), MYL: 42.36 (-0.39), LLY: 77.75 (-0.02), AMPH: 19.00 (-0.45)

Forget Allergan & Pfizer, Buy These Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Tue Nov 24, 11:09AM CST
Let's take a look at some drug stocks with an attractive Zacks Rank and positive estimate revisions.
AGN: 234.54 (-2.45), NVO: 46.72 (-0.41), PTX: 0.64 (+0.04), PFE: 34.80 (-0.08), MYL: 42.36 (-0.39), LLY: 77.75 (-0.02), AMPH: 19.00 (-0.45)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Pernix Therapeutics Holdings, Inc. - PTX
ACCESSWIRE - Mon Nov 16, 3:30PM CST
NEW YORK, NY / ACCESSWIRE / November 16, 2015 / Levi & Korsinsky announces it has commenced an investigation of Pernix Therapeutics Holdings, Inc. (NasdaqGM: PTX) concerning possible breaches of fiduciary duty by its Board of Directors. To obtain additional information, GO TO:
PTX: 0.64 (+0.04)

Pernix Therapeutics to Present at Stifel 2015 Healthcare Conference
GlobeNewswire - Fri Nov 13, 6:00AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the Stifel 2015 Healthcare Conference as follows:
PTX: 0.64 (+0.04)

Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From a Phase IV Study to Assess and Compare the Effects of Silenor 6 mg and zolpidem 10 mg on Balance, Cognitive Performance, and Arousability
GlobeNewswire - Thu Nov 12, 10:15AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV Study assessing the effects of a nighttime administration of Silenor 6 mg, zolpidem 10 mg, and placebo on arousability, gait/balance, and cognitive performance in healthy volunteers. The study assessed the effects of a single dose of Silenor 6 mg compared with matching placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the respective Tmax (amount of drug present at the maximum serum concentration) in normal healthy adult male volunteers (n=39). The interim results of this head-to-head comparison demonstrate that Silenor 6 mg is statistically significantly superior to zolpidem 10 mg on all measures analyzed. The results also indicate that subjects taking Silenor 6 mg did not have impairment on any of these measures and were comparable to placebo. Further, Silenor 6 mg and both placebo groups were superior to zolpidem on all measures, indicating that zolpidem subjects had significant difficulty waking up, difficulty in their ability to walk, difficulty with balance, and experienced memory impairment.
PTX: 0.64 (+0.04)

Pernix Therapeutics to Host Meetings at Upcoming Conferences
GlobeNewswire - Tue Nov 10, 3:30PM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host investor meetings at two upcoming conferences:
PTX: 0.64 (+0.04)

The Zacks Analyst Blog Highlights: Teva Pharmaceutical Industries, Mylan, Impax Laboratories, Teligent and Pernix Therapeutics Holdings
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 8:30AM CST
The Zacks Analyst Blog Highlights: Teva Pharmaceutical Industries, Mylan, Impax Laboratories, Teligent and Pernix Therapeutics Holdings
IPXL: 24.19 (-0.23), PTX: 0.64 (+0.04), MYL: 42.36 (-0.39), TEVA: 50.39 (-0.17), TLGT: 7.42 (-0.21)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Karen Love's Retirement Marks End of an Era for TACHP

A Legacy Not Just Built, But Carved in Stone In the world of healthcare, folks like Karen Love don’t come around too often. She's stepping down from her post as President and CEO of Cook Children's Health Plan this month, and it feels like the end of a chapter for the Texas Association of Community Health Plans (TACHP). Love wasn't just an executive; she was a mover and...

Ace Hardware Ups the Stakes with Rewards Days Event

Ace Hardware: Doubling Down with Rewards Ace Hardware's rolling out the red carpet for its loyal customers. Imagine this: exclusive deals on trusted brands and double points on purchases—an incentive any savvy shopper would jump at. From October 6 to 7, those in the Ace Rewards circle have the chance to nab some hefty savings and perks, a move that's more than just a...

Gateway Unveils All-In-One Award Travel Platform

Transforming Loyalty with point.me's Gateway Here's the deal: the loyalty program game just changed. Point.me rolled out this slick beast called Gateway, and it's weaving award travel booking right into your everyday banking apps. That's right, ditch those clunky third-party sites, because now you can browse, compare, transfer, and book your award travel directly from...

Varda Space's Dual Launch Signals Orbital Ambitions

It's not every day you see two commercial rockets heading to orbit on the same ride, but that's precisely what Varda Space Industries just pulled off. With the W-8 and W-9 vehicles blasting off together, Varda is positioning itself for a leap in orbital operations. They've hitched a ride aboard SpaceX's Transporter-18 mission, and this is more than just a double...

Concrete Pipe: Foundation of Modern Infrastructure

Reinforced Concrete Pipes Hold Their Ground You know, it might not be the flashiest part of our infrastructure toolkit, but concrete pipe plays a mighty big role behind the scenes. Even in this age of shiny new tech and constantly evolving materials, the classic concrete pipe still packs a punch—especially when you demand something that'll last. Enter Stephanie Ward, a...

Fresh Leadership at Master Group: Langelier Steps In

Changing of the Guard: A Calculated Move It's not every day you see a company make a move as calculated and thoughtful as the one the Master Group just pulled. Rémy Langelier is set to transition into the shoes of CEO by early 2027, fresh off the heels of Louis St-Laurent. This isn't just any executive shuffle, folks—it's a strategic baton pass spawning an investment...

Cannatrol and Veterans Nonprofit Unite for Healing

Veterans Find a New Ally in Cannabis Tech When two distinct worlds collide for a cause, it can create waves of change much bigger than simple collaboration. That's exactly what's happening with Cannatrol and Operation Green Healing, a partnership that could redefine support for our veterans. Cannatrol, renowned for its groundbreaking post-harvest cannabis technology, has...

Texas A&M-San Antonio's Research Expansion Momentum

Texas A&M-San Antonio's Rising Research Ambitions A rainy day in San Antonio and Texas A&M University-San Antonio seems to have set the stage for more than just another semester of record enrollment. They’ve just rolled in with an exhilarating $8 million in external grants this fiscal year, more than doubling last year’s haul of $3.6 million, in a bid to push their...

Neutonic Sets Sights on U.S. with Walmart Expansion

Neutonic Embarks on Major Expansion with Walmart Well, here we go. Neutonic is stepping up to the big leagues by planting its flag in nearly 1,000 Walmart stores across the U.S. This move lands them right in the thrumming heart of Walmart's new Mood & Mind beverage set. It's about time this brand brings its functional beverages to American shoppers already drained by...

Haystack MRD Shines in Colorectal Cancer Trials

A New Dawn in Cancer Detection Just when you think you've seen it all in cancer diagnostics, Haystack MRD® pops up like a fresh tulip in spring. And listen, this ain't just fluff—the results from the DYNAMIC trials are a pretty compelling love letter to the power of liquid biopsy. With 100% specificity and sensitivity hitting a whopping 83.3% over five years, it’s...